Early Physician Experiences with Embrace™ Hydrogel Embolic System
Achieving Distal Penetration & Maintaining Control
Moderated by Michael C. Soulen, MD FSIR FCIRSE, this peer-led webinar features real cases from clinical practice presented by Nadine Abi-Jaoudeh, MD FSIR CCRP, Resmi A. Charalel, MD MPH, David Tahour, MD, and Edgar St. Amour, MD — across HCC, liver metastases, angiomyolipoma, and pre-resection embolization.
The Panelists
Michael C. Soulen, MD
FSIR, FCIRSE
Moderator
Nadine Abi-Jaoudeh, MD
FSIR, CCRP
Clinical Data Insights & Case Review
Resmi A. Charalel, MD
MPH
Case Review
David Tahour, MD
Case Review
Edgar St. Amour, MD
Case Review
Embrace™ Hydrogel Embolic System
Embrace™ HES is the first and only FDA-approved liquid embolic for hypervascular tumor embolization supported by a prospective, randomized clinical trial. The only non-adhesive liquid embolic penetrating to the capillary level, it delivers proven targeted hypervascular tumor treatment and favorable target lesion response without recanalization.